Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_3608_Библиотеки_им_академика_М_И_Перельмана
.pdf
% Prevalence
Rotterdam study
60
(Meijer, 1998)
213
FIGURE 161 Peripheral artery disease
(PAD) prevalence. Estimates based on ankle-
brachial index (ABI) from six large studies.
50
40
30
20
10
0
40 50 60 70 80 90
Age
Hoorn study, men
(Beks, 1995)
Hoorn study, women
(Beks, 1995)
San Diego population
study (Criqui, 1985)
Limburg study, men
(Stoffers, 1996)
Limburg study, women
(Stoffers, 1996)
Cardiovascular health
study, ex CVD, men
(Newman, 1993)
Cardiovascular health
study, ex CVD, women
(Newman, 1993)
Honolulu heart program,
men only, (Curb, 1996)
CH
16
THE EPIDEMIOLOGY OF PERIPHERAL ARTERY DISEASE
estimates in men and women were similar by age 65 to 74. In a
group of Israeli men, incidence of claudication ranged from 6.3
per 1000 per year at ages 40 to 49 to 10.5 per 1000 at age 60 and
greater.
dence rose from 0.7 per 1000 per year at ages 35 to 44, to 3 per
1000 per year at ages 45 to 54, 7 per 1000 per year at ages 55 to 63,
and 9 per 1000 at age 65 and greater.
followed English men aged 45 to 63 years for 10 years, claudication incidence per 1000 per year ranged from 3.1 in the youngest
to 4.9 in the oldest age group, based on age at baseline examination.
among men and women aged 55 to 74 in the Edinburgh Artery
Study; however, this study did not apply strict Rose criteria for
probable claudication.
techniques to conclude that intermittent claudication rates among
Icelandic men dropped significantly between 1968 and 1986.
Among 50-year-old men, their estimate of the rate of claudication
dropped from 1.7 per 1000 per year in 1970 to 0.6 per 1000 per
year in 1984, whereas in 70-year olds, the rate of claudication
dropped from 6.0 to 2.0.
smoking and cholesterol levels. The design and duration of this
study were uniquely suited to estimating long-term trends in
disease incidence; comparable studies for other populations are
unavailable. The potential for trends of this magnitude should be
considered in reviewing results of other studies. Figure 16-2 shows
incidence rates by age for various studies identifying PAD based
on claudication.
time and resources required to periodically retest study subjects
for incident disease. In the Limburg PAOD Study, incidence rates
for PAD were based on two ABI measurements of less than 0.95.
Among men, annual incidence was 1.7 per 1000 at ages 40 to 54; 1.5
per 1000 at ages 55 to 64; and 17.8 per 1000 at ages 65 and greater.
1
In a study of 4570 men from Quebec, claudication inci-
38
In the Speedwell Study that
39
A higher incidence of 15.5 per 1000 per year was reported
40
In the Reykjavik Study, Ingolfsson et al. used Poisson regression
41
The authors attributed this to decreased
1,37–39,41
There are very few ABI-based studies of PAD incidence, given the
Annual incidence in women was higher: 5.9, 9.1, and 22.9 per 1000,
respectively, for the same age groups.
42
Sex differences in incidence and prevalence of PAD are less
clear than those in other cardiovascular diseases.
Claudication incidence and prevalence have usually been
found to be higher in men than women. For example, in the
Framingham Study, annual claudication incidence for all ages
combined was 7.1 per 1000 in men versus 3.6 per 1000 in women,
for a male-to-female ratio of 1.97.
37
In the Framingham Offspring
Study, claudication prevalence was 1.9% in men versus 0.8%
in women (ratio = 2.38), whereas in the Rotterdam Study it was
2.2% in men versus 1.2% in women (ratio = 1.83).
10,30
However, the
Edinburgh Artery Study and the Limburg PAOD Study found much
lower male-to-female ratios of claudication prevalence of 1.11 and
1.2, respectively.
23,35
The case for an excess of disease among males is even weaker for
PAD diagnosed based on ABI. This is true even in those studies finding a clear male excess with respect to claudication. For example,
in the Framingham Offspring Study mentioned earlier, PAD based
on ABI was found in 3.9% of men and 3.3% of women, for a ratio
30
of 1.18.
in men than in women, with prevalences of 16.9% and 20.5% for
a ratio of 0.82
In the Rotterdam Study, ABI-based PAD was actually lower
10.
The Limburg PAOD Study, which reported a low
male-to-female ratio for claudication, reported a similarly low ratio
of 1.1 for ABI-based PAD.35 A population-based study from Southern
Italy found prevalences of PAD based on ABI of less than 0.9 to be
very similar in men and women, with male to female ratios by age
of .89 to .99.
43
In the CHS, ABI of less than 0.9 was somewhat more
prevalent in men than women (13.8% vs. 11.4%; ratio = 1.21), but the
association of disease with sex was not significant after adjustment
for age and cardiovascular disease status.
15
In the Atherosclerosis
Risk in Communities (ARIC) Study, PAD prevalence based on
ABI was actually lower in men than women among both African
Americans (3.3% vs. 4.0%) and whites (2.3% vs. 3.3%).
44

214
Annual incidence per 1000
12
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
CH
16
10
8
6
4
2
0
40 50 60 70 80 90
Age
Framingham men
(Kannel, 1985)
Framingham women
(Kannel, 1985)
Israeli men
(Bowlin, 1994)
Quebec men
(Dagenais, 1991)
Speedwell men
(Bainton, 1994)
Reykjavik men 1984
(Ingolfsson, 1994)
Reykjavik men 1970
(Ingolfsson, 1994)
FIGURE 162 Peripheral arte ry diseas e
(PAD) incidence. Estimates based on
claudication from five large studies.
The greater male excess observed for symptomatic versus
ABI-diagnosed disease may be related to severity of disease.
A prevalence study in Southern California found that the excess
of disease among males increased with severity of PAD.33 A report
from the Multi-Ethnic Study of Atherosclerosis (MESA) showed
PAD prevalence (ABI of less than 0.90) was the same in men and
women (3.7%), but borderline values of ABI (0.90-0.99) were much
higher in women (10.6% vs. 4.3%).
Peripheral Artery Disease Risk Factors
The section that follows reviews existing evidence for the association of various possible risk factors with PAD. It begins with a
discussion of traditional risk factors long implicated in atherosclerotic processes underlying coronary heart and cerebrovascular disease, and then moves on to a discussion of emerging or
“novel” risk factors. Where applicable, information on interaction
between risk factors and the impact of risk factors on the natural
history of disease are also provided.
The study of PAD epidemiology raises a number of methodological issues that should be kept in mind while reviewing the literature.
As discussed earlier, the definition of disease has evolved over time, with
earlier studies focusing more on claudication as measured using
Rose and other criteria, and later studies using the ABI with a value
of 0.9 or less, now widely used to define disease. These different
potential definitions are noted throughout.
Methodologically, the strongest epidemiological evidence
for a causal relationship between disease and putative risk factors comes from studies of incident disease. Such studies usually
involve measurement of risk factors at a baseline examination,
with subsequent tracking of incident disease among the subjects.
Acute events such as myocardial infarction (MI) and stroke lend
themselves to such study because the date of onset of disease is
generally documented in the records of healthcare providers and
recalled by subjects. Conversely, the onset of PAD as defined by
ABI is often asymptomatic, and in any case is unlikely to be documented other than through periodic reexamination of all the subjects, which involves substantial time and expense. For that reason,
many studies of PAD risk factors are based on cross-sectional associations; that is, the association between current disease status and
current risk factor measurements. Although such studies are potentially informative, reported associations cannot conclusively prove
causation because it is not known whether the risk factor preceded
the disease or vice versa. Caution should therefore be exercised in
reviewing results of such cross-sectional studies, particularly where
reverse causation is plausible. For example, low physical activity
might cause claudication, but claudication might just as plausibly
cause low physical activity.
It is necessary to adjust for multiple potential risk factors in a single
statistical model to accurately estimate the unique contribution of
any single risk factor because the potential risk factors for PAD
are themselves interrelated in various ways. Estimates presented
45
subsequently are based on such multiple adjustment for all
traditional PAD risk factors except as noted. Null findings may
indicate lack of a real association but may also be based on insufficient sample size. Most of the null findings discussed are based on
failure of the risk factor of interest to remain statistically significant
in stepwise regression models, which vary as to their algorithms for
variable selection.
The following discussion of risk factors focuses on the results
from five large epidemiological studies referred to as index studies
(
Table 16-2). These studies each had over 3000 subjects drawn from
the general population and included both men and women. The
studies are similar enough in their selection and manner of measuring risk factors and in their statistical analyses to allow reasonable
comparisons for most of the common risk factors. Although the
discussion draws on data from many other studies (see
Table 16-2
for a partial list), data are presented from these five studies across
all the conventional cardiovascular disease risk factors to provide
some consistency and comparability for the reader, and as a check
against potential biases that might be introduced by selecting all
the studies to present for each risk factor in a more ad hoc fashion.
Smoking
Smoking is one of the strongest risk factors for PAD in virtually all
studies. Studies vary as to their measurement of smoking, often combining a categorical assessment of smoking status (current, past, or
never) with some measure of current or historical volume of smoking; these multiple approaches to measurement make comparisons
difficult. However, even with some type of additional adjustment for
volume of smoking, current smoking versus nonsmoking has been
shown to at least double the odds of PAD in most studies, with some
estimates as high as a four times greater risk among smokers than
others. Among the index studies, current smoking (vs. never or former/never) resulted in 2.0 to 3.4 times higher odds of PAD in the
three studies using such categorization; however, in two of these
studies, the models also included pack-years of smoking as a significant variable. The Rotterdam study included only current packs/day,
showing a doubling of the odds of PAD for each pack a day smoked
(
Table 16-3). All the large population-based studies reviewed found
a significant independent association between PAD and smoking.

TABLE 16-2 Population-Based Studies of Peripheral Artery Disease
STUDY NAME
Index Studies
Framingham Study Murabito, 1997 5209 United States Cross-sectional IC
Framingham Offspring Study Murabito, 2002 3313 United States Longitudinal ABI < 0.9
Cardiovascular Health Study Newman, 1993 5084 United States Ages 65+ Cross-sectional ABI < 0.9
Rotterdam Study Meijer, 2000 6450 Netherlands Cross-sectional ABI < 0.9 (<.7 also studied)
Multi-Ethnic Study of
Atherosclerosis
Other Large Studies
Honolulu Heart Program Curb, 1996 3450 United States Japanese American
Edinburgh Artery Study Fowkes, 1992 1592 Scotland Cross-sectional ABI and reactive hyperemia
Limburg PAOD Study Hooi, 2001 2327 Netherlands Longitudinal ABI < 0.95
Israeli Ischemic Heart Disease Bowlin, 1994 10,059 Israel Middle-aged men Longitudinal IC projected
Reykjavik Study Ingolfsson, 1994 9141 Iceland Men only Longitudinal IC
Quebec Cardiovascular Study Dagenais, 1991 4570 Canada Men only Longitudinal IC
Physicians’ Health Study Ridker, 2001 14,916 United States Male physicians Nested case-control IC or PAD surgery
San Diego Population Study Criqui, 2005 2343 United States Multiethnic Cross-sectional ABI ≤ 0.9, abnormal
*
Where multiple papers were published, this refers to the paper most frequently referenced herein.
ABI, ankle-brachial index; IC, intermittent claudication, PAD, peripheral artery disease.
FIRST AUTHOR,
YEAR*
Allison, 2006 6653 United States Cross-sectional ABI ≤ 0.9
NO. OF
SUBJECTS COUNTRY
POPULATION
CHARACTERISTICS STUDY DESIGN
men
Cross-sectional and
longitudinal
PAD ENDPOINT
ABI < 0.9
waveform, PAD
revascularization
TABLE 16-3 Smoking as a Peripheral Artery Disease Risk Factor
95% CI
STUDY VARIABLE ODDS RATIO LOW HIGH
Framingham Study Current packs/day 1.96 1.69 2.25
Framingham Offspring Study Current smoker (vs. former or never) 2.00 1.10 3.40
Pack-years of smoking 1.03 1.02 1.03
Cardiovascular Health Study Current smoker (vs. former or never) 2.55 1.76 3.68
Pack-years of smoking 1.01 1.01 1.02
Rotterdam Study Current smoker (vs. never) 2.69 1.67 4.33
Former smoker (vs. never) 1.15 0.75 1.78
Multi-Ethnic Study of Atherosclerosis Current smoker (vs. never) 3.42 2.48 4.73
215
CH
16
THE EPIDEMIOLOGY OF PERIPHERAL ARTERY DISEASE
Cessation of smoking among patients with claudication has
been shown to improve various functional and physiological measures related to PAD, as well as reducing mortality.
46–48
However,
because symptomatic PAD patients have long been advised to quit
smoking, it is possible that observational comparisons of patients
who quit smoking with those who do not are confounded by other
differences in compliance with medical advice between the two
groups. Randomized trials of this question would raise ethical
issues, but substantial bias is unlikely, given the large effect size
for cigarette smoking.
Aside from the large increase in risk associated with it, smoking
is the traditional risk factor for which the best case can be made for
a more important role in PAD than in other atherosclerotic diseases.
In a comparison of risk factors conducted in the same large cohort,
Fowkes et al. found smoking to be associated with a significantly
higher relative risk for PAD compared to other cardiovascular
diseases. Smoking was the only traditional cardiovascular disease
risk factor for which the odds ratio differed signi ficantly between
PAD and other cardiovascular diseases.
49
Diabetes
Diabetes is strongly associated with an elevated risk of PAD,
although the evidence for an independent role in multivariable
analysis is not entirely consistent. Four of the five index studies
found diabetes, dichotomized based on different criteria, to be
associated with PAD after multivariable adjustment, with odds
ratios ranging from 1.89 to 4.05.
Study found such an association on an age- and sex-adjusted basis,
but not in multivariable models.
9,15,50,51
The Framingham Offspring
30
Among other large population-based studies, multivariable logistic regression models have often shown a relationship to diabetes
as a categorical variable,
as linear variables.
sugar measures were seen in the Edinburgh Artery Study
Reykjavik Study.
41
1,34,36,42,52
39
Other null findings for diabetes or blood
or various blood sugar measures
49
and the
More severe and/or long-standing diabetes appears to be more
strongly related to PAD. In the Hoorn Study, it was shown that known
diabetes was associated with PAD in multivariable analysis, whereas
newly diagnosed diabetes was only of borderline significance, and
impaired glucose tolerance was not associated with PAD.34 In that
study, after excluding known diabetics, none of the common glycemic indices that were tested were significantly associated with PAD bas ed
on ABI, although significant associations were observed when the
PAD criteria were broadened to include patients with additional criteria.
Studies conducted in patients with diabetes have shown that duration of
diabetes and use of insulin are associated with PAD.
53–55
Outcomes of PAD in diabetic patients have been shown to
be worse. In one study, diabetic patients with PAD were five times
more likely to have an amputation than other PAD patients; they
also had more than three times the odds of mortality.
56
There is also
some evidence to support a somewhat different anatomical distribution of disease, with more disease in arteries distal to the knee
in diabetic than nondiabetic persons.
56,57

216
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
Lipids
As is the case in cardiovascular disease epidemiology, the challenge of defining the roles of various lipid fractions in PAD lies
in identifying the strongest independent risk factors from among
multiple correlated measures. In recent studies, recognition that
CH
the ratio of total cholesterol to high-density lipoprotein (HDL)
16
cholesterol is the best lipid measure of risk,58 along with increasing
use of medication, has led to analyses that employ both these variables in the same model
in a single variable (e.g., “dyslipidemia”).
studies appear in
Total cholesterol was the first lipid measure examined as a
potential risk factor for PAD and has been the most widely studied.
Total cholesterol was examined as a potential risk factor in four
of the index studies, and was significantly associated with PAD
in multivariable analysis in three. In the remaining study, total
cholesterol was significant in univariate analysis but dropped
out of multivariable models that considered other lipid mea-
30
sures.
Similarly, in other studies total cholesterol has usually
been found to be associated with PAD,
null findings in multivariable analyses where other lipid measures
are considered.
terol as the sole lipid measure was an analysis of the Quebec
Cardiovascular Study cohort.
High-density lipoprotein cholesterol (HDL-C) has been shown
to be protective against PAD in most studies where it was evaluated, usually in models that also considered total cholesterol.
High-density lipoprotein cholesterol was included among potential risk factors in three of the five index studies and in the TC/
HDL-C ratio in a fourth, and was significantly associated with PAD
in multivariable analysis in all four. In two studies, both HDL-C and
total cholesterol were significant in multivariable analysis, whereas
in one study HDL-C but not total cholesterol was significant. Other
studies have also shown a protective effect of HDL-C.
Bowlin et al. found that non-HDL cholesterol (total cholesterol
minus HDL cholesterol) was significantly associated with incident
claudication in a large cohort of Israeli men. Neither total cholesterol nor HDL cholesterol were significantly associated with
disease in models that included non-HDL cholesterol.
parison of incident cases of claudication with healthy controls
in the Physician's Health Study, Ridker et al. found that the ratio
of total to HDL cholesterol was the lipid measure most strongly
associated with disease, with patients in the highest quartile having 3.9 times the claudication risk of patients in the lowest quartile.
Screening for other lipid fractions was judged to have little clinical
usefulness beyond measurement of this ratio.
Evidence for high triglycerides as an independent risk factor for
PAD is fragmentary. Early case-control studies showed a very consistent relationship between triglycerides and PAD, suggesting a
uniquely strong relationship with PAD, but large population-based
52
or combine the ratio with medication use
51
Results from the index
Table 16-4.
1,36,41,49
with occasional
39,59
One of the few null findings for total choles-
38
36,59
60
1
In a com-
cohort studies employing multivariable modeling later called this
into question.
49,61
Among the index studies, only two included triglycerides among the potential risk factors evaluated. In both cases,
triglycerides were significant in univariate analysis but dropped out
of multivariable models based on stepwise logistic regression.
15,30
Similarly, in the Edinburgh Artery Study cohort and in a large study
of geriatric patients in the United States, triglycerides were not
significantly associated with PAD after adjustment for other lipid
meaures.
significantly and independently associated with PAD in multivariable analysis.
vated triglycerides may have a special role in disease progression
or more severe PAD.
49,59
However, other studies have shown triglycerides to be
39,53,62
There is also some evidence suggesting that ele-
49,63
In summary, although total cholesterol, HDL-C, and triglycerides
all appear to be associated with PAD on a univariate basis, in multivariable analysis triglycerides frequently drop out as an independent risk factor. Although it has been the most extensively studied,
it is not clear that total cholesterol is the strongest independent risk
factor for PAD; in one comparison of PAD patients with healthy controls, it was found that mean total cholesterol did not differ significantly, whereas triglycerides, very low-density lipoprotein (VLDL)
cholesterol, low-density lipoprotein (LDL) cholesterol, HDL cholesterol, and the total-to-HDL cholesterol ratio all did.
64
Total and HDL cholesterol seem to provide distinct information and lend themselves to summarization in a single ratio.
Because many early studies considered only total cholesterol,
full resolution of the question of which lipid measures are most
strongly and independently related to PAD awaits completion
of additional large-scale studies that assess all relevant lipid risk
factors. Irrespective of results from multivariable analysis, simple
descriptive statistics and clinical observation both suggest that
PAD patients are frequently diabetic or insulin resistant, with the
typical dyslipidemia of insulin resistance (i.e., low HDL and high
triglycerides).
Hypertension and Blood Pressure
The association of hypertension with PAD has been demonstrated
in most studies in which blood pressure was studied. All five of the
index studies reported a significant association between hypertension as a categorical variable and PAD. The lowest reported odds
ratio was 1.32 as reported in the Rotterdam Study; this is somewhat understated relative to the others, since it was based on a
model that included both a categorical hypertension variable and
an adjustment for systolic blood pressure level that was also significant.
1.50 to 2.20. Most other large population-based studies have also
found a significant independent association of hypertension or
systolic blood pressures with PAD.
systolic pressure was usually found to be associated with PAD,
9
Other than this, odds ratios for hypertension ranged from
38,39,42,49,52
Where both systolic and diastolic pressures were considered,
TABLE 16-4 Lipid Measures as Peripheral Artery Disease Risk Factors
95% CI
STUDY VARIABLE ODDS RATIO LOW HIGH
Framingham Study*
Framingham Offspring Study
Cardiovascular Health Study
Rotterdam Study
Multi-Ethnic Study of Atherosclerosis
*
Only total cholesterol was tested.
†
Hypercholesterolemia (≥240 mg/dL or medication) and triglycerides dropped out of stepwise logistic regression model.
‡
Triglycerides dropped out of stepwise logistic regression model.
§
Triglycerides not tested.
||
Total/HDL cholesterol ratio > 5.0 or lipid medication use.
HDL, high-density lipoprotein.
§
†
‡
||
Total cholesterol (10 mg/dL) 1.05 1.02 1.07
HDL cholesterol (5 mg/dL) 0.90 0.80 1.00
Total cholesterol (10 mg/dL) 1.10 1.06 1.14
HDL cholesterol (5 mg/dL) 0.95 0.90 1.00
Total cholesterol (10 mg/dL) 1.05 1.01 1.08
HDL cholesterol (5 mg/dL) 0.93 0.87 1.00
Dyslipidemia (yes/no) 1.58 1.22 2.05

whereas diastolic pressure was not significantly associated
or had a nonlinear relationship with PAD.
36
Two large studies
9,15,65
found no relationship of blood pressure with PAD. In the Israeli
Ischemic Heart Disease Project cohort, neither systolic nor diastolic blood pressure was associated with claudication,
1
whereas
in the Reykjavik Study, systolic and diastolic blood pressures were
significantly associated with claudication in cross-sectional but
not longitudinal models.41 It is interesting to note that both of
these studies appear to have used blood pressure as a linear term
in their models. Most other recent large studies have used a categorization of subjects into normotensive and hypertensive groups
based on systolic and diastolic pressures as well as hypertension
medication use.
Both of the null findings also come from studies in which claudication was the outcome of interest. It has been speculated that
elevated central perfusion pressure as indicated by (axial) blood
pressure will sometimes delay onset of claudication by increasing
blood pressure in the lower extremities, which—if true—would
obscure the relationship of hypertension with underlying disease
processes.
66
However, randomized trials of blood pressure lower-
ing in PAD patients generally do not report worsened claudication.
Although the relative risks associated with hypertension are modest in some studies, its high prevalence, particularly among older
patients, make it a significant contributor to the total burden of PAD in
the population. For example, in one large study from the Netherlands,
the odds ratio for hypertension was 1.32, but its attributable risk (a
measure of the proportion of PAD due to hypertension in the population) was 17.0%, second only to current smoking in this group.
Framingham Study, 30% of the risk of claudication in the population
was attributable to blood pressure in excess of 160/100.
9
In the
50
Obesity
To date, the preponderance of evidence fails to support a consistent independent positive association between obesity and PAD.
In one of the few large studies with a positive finding, Bowlin et al.
estimated an odds ratio of 1.24 (95% confidence interval [CI], 1.05-
1.46) for incident claudication related to a 5.0 kg/m2 difference in
body mass index (BMI) in a study of 10,059 Israeli men.
Three of the index studies and a number of other large population-based studies have failed to find a significant association
between obesity and PAD or claudication after multivariable adjust-
9,30,41,42,51,59
ment.
There have also been many studies, including the
other two index studies, in which higher relative weight or BMI was
actually shown to be protective against PAD. In the Framingham
Study, claudication was significantly inversely related to relative
weight in men in multivariable analysis, and appeared to have a
“U-shaped” nonlinear relationship with relative weight in women.
In an analysis from the Edinburgh Artery Study, BMI was significantly associated with less disease in preliminary multivariable
analysis, although BMI was excluded from the paper's final multivariable model because it “suggested a counterintuitive effect.”
The CHS found higher BMI to be significantly protective against PAD
after multivariable adjustment in a large sample of Medicare benefi-
15
ciaries.
(defined based on a combination of ABI, Doppler flow curves, and
history of surgery) in the Hoorn Study.
Body mass index was significantly protective against PAD
34
Similarly, the odds of PAD
among subjects in the highest quintile of BMI compared with the
lowest quintile were found to be significantly reduced in a crosssectional analysis of elderly Japanese American men.
with higher BMI were again shown to be at significantly lower risk
of PAD in a study of Taiwanese subjects with diabetes.
multiethnic San Diego Population Study (SDPS) reported a significant inverse association for BMI and PAD.
52
Obesity has been implicated in the etiology of other risk factors for PAD, such as hypertension, type II diabetes, and dyslipidemia. In epidemiology, adjusting for factors that are on the causal
pathway between a risk factor and disease is known to attenuate
the observed strength of that risk factor. Therefore, estimates of risks
related to obesity in multivariable models are estimates of the risk
1
36
Subjects
67
Finally, the
37
49
of obesity that artificially ignore most of the mechanisms by which
obesity might reasonably cause PAD. In a few cases, unadjusted
models or models adjusted only for age and sex show a significant
association with PAD, even though obesity was nonsignificant or
protective after multivariable adjustment.
30,49,59
However, in other
studies, obesity was found to be either protective or nonsignificant
even in unadjusted models or models adjusted only for age and
9,15,36,37,39
sex.
Thus, the failure to find more cases of positive association between PAD and obesity is not simply an artifact of adjusting for factors on the causal pathway in multivariable modeling,
but seems to suggest a real lack of consistent evidence that such a
relationship exists at all.
Unaccounted for in the multivariable analyses just cited is possible residual confounding by cigarette smoking, which is strongly
associated with both PAD and lower BMI. In addition, chronic illness in older persons, including PAD, may lead to weight loss and
allow for a spurious inverse correlation between obesity and PAD.
As in coronary heart disease (CHD) epidemiology, there is some
evidence to suggest that central adiposity, rather than obesity per
se, may be more closely related to an increased risk of PAD. Vogt
et al. found that after adjustment for BMI, higher waist/hip ratio
was associated with significantly higher risk of PAD.6 In a group of
patients with diabetes, it was shown that waist/hip ratio, but not BMI
or body fat percentage, was associated with PAD.
53
Alcohol Consumption
Evidence for a protective effect of light to moderate alcohol consumption, as seen in CHD, is less consistent for PAD. Two of the five index
studies considered alcohol intake; neither showed alcohol to be significantly associated with PAD in either age- and sex-adjusted or multivariable models.
these studies, a significant protective effect was found in women but
not men.
68
but not women in the Edinburgh Artery Study, but this association
disappeared after adjustment for social class.
9,30
However, in a later analysis of data from one of
Conversely, a protective effect of alcohol was seen in men
69
In Native Americans,
a protective effect of alcohol was seen in multivariable analysis,
but in elderly Japanese American men, alcohol intake was found to
increase rather than decrease the risk of incident PAD.36 Data from
the Physician's Health Study suggest that a protective effect related to
moderate alcohol consumption may exist.
71
In that study, there was no
univariate association between alcohol and claudication incidence,
but adjustment for cigarette smoking “unmasked” a significant protective association, reflecting the positive correlation of alcohol consumption with smoking, a strong risk factor for PAD. Based on this, it
seems possible that incomplete adjustment for smoking in other studies might allow residual confounding that could obscure any protective effect of alcohol, despite multivariable adjustment.
Race and Ethnicity
Data on the association of race with PAD are limited because many
large studies of PAD have been conducted in non-Hispanic white
groups. A 2003 review of ethnicity and PAD concluded that there
were “no large population-based studies assessing the prevalence
of PAD in non-Caucasians.”
Several studies suggest a higher risk of PAD among blacks. The CHS,
a study of 5084 Medicare beneficiaries in the United States, found
that nonwhite (mostly black) race was associated with an odds
ratio of 2.12 for PAD after adjustment for traditional risk factors.
A study of 933 women aged 65 and older found a higher percentage
of black subjects among the PAD (36.3%) versus non-PAD (24.8%)
17
groups.
In the ARIC Study, Zheng et al. found that PAD prevalence
was higher in African Americans than whites in both men (3.3% vs.
2.3%) and women (4.0% vs. 3.3%).
able odds ratio of 1.67 for blacks versus non-Hispanic whites.51 The
SDPS reported an odds ratio of 2.34 for blacks versus non-Hispanic
whites after adjustment for hypertension and diabetes,
tional analyses also showed no evidence of a greater sensitivity of
blacks to traditional cardiovascular disease risk factors. Finally, a
72
44
The MESA reported a multivari-
52
and addi-
217
CH
16
THE EPIDEMIOLOGY OF PERIPHERAL ARTERY DISEASE
70
15

218
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
synthesis of three studies addressing this question reported odds
ratios of 2.3 to 3.1 for blacks versus non-Hispanic whites adjusted
for age and gender; odds ratios of 1.7 to 2.9 after adjustment for
traditional risk factors; and odds ratios of 1.5 to 2.0 after further
adjustment for novel risk factors including inflammatory risk fac-
73
tors.
CH
16
Thus, this association is in part explained by traditional risk
factors and in part by novel risk factors, but there is an unexplained
residual difference. Interestingly, hospital-based studies suggest that
anatomical distribution of disease may differ in blacks, with a higher
percentage of distal disease in black subjects, even after adjustment
for diabetes and other cardiovascular risk factors.
72
Data on other races and ethnic groups are limited. In a study in
Honolulu, Hawaii, Asians were reported to have lower PAD prevalence than comparable non-Hispanic white subjects.
MESA and the SDPS data suggest somewhat lower rates of PAD in
Asians and Hispanics than in non-Hispanic whites.
Native Americans suggested PAD prevalence comparable with that
in non-Hispanic whites.
70
51,52
Homocysteine
The association of homocysteine with PAD has been examined
in a number of studies, with conflicting results. A 1995 meta-analysis of
early case-control studies conducted in the late 1980s and early
1990s suggested an odds ratio of 6.8 for a 5 μmol/L difference in
fasting total homocysteine (tHcy).
74
To put this in perspective, the
differences between the 25th and 75th percentiles of tHcy among
controls in the Physician's Health Study and a study of women in
the Netherlands were between 3.5 and 4.0 μmol/L.
60,75
difference noted is therefore not unreasonable as the difference
between low and high tHcy levels in the population. In that light,
an odds ratio of 6.8 might make homocysteine the single most
powerful risk factor for PAD. Interestingly, the odds ratio for PAD
in the meta-analysis was strikingly higher than the odds ratios for
coronary artery disease (CAD) and cerebrovascular disease, which
were below 2 in the same study.
However, more recent studies have produced much lower and
frequently nonsignificant estimates of the PAD risk associated with
homocysteine. In a large European case-control study, Graham et al.
estimated an odds ratio of 1.7 for subjects in the top quintile of homocysteine for their control group versus all other subjects—a result
of only borderline statistical significance.
76
One population-based
study from the Netherlands found a 1.44 odds ratio for a 5 μmol/L
difference in fasting tHcy, based on an extreme definition of PAD
involving surgery or an ABI of less than 0.5.
77
However, an analysis
of a subset of the Rotterdam Study cohort found no significant relationship between tHcy and PAD, based either on the conventional
0.9 ABI cut-off or on a 0.7 ABI cut-off for severe disease.
reported a significant association for homocysteine after multivariable adjustment for traditional risk factors, but the association just
missed significance after adjustment for other novel risk factors.
nested case-control study using the Physician's Health Study cohort
failed to find any association between quartiles of fasting tHcy and
claudication.
Netherlands also failed to find any significant association between
fasting homocysteine and symptomatic PAD.
60
A recent case-control study of young women in the
75
Among patients with
PAD, disease progression based on ABI was not significantly different
in patients with the highest and lowest 20% of homocysteine levels.
At this point, although it is still possible that homocysteine may
be an independent risk factor for PAD, it appears that the early
results summarized in the 1995 meta-analysis may have overstated
the importance of homocysteine. This may be related to the quality
of the studies included in the meta-analysis, which included primarily small case-control studies.
74
C-Reactive Protein and Fibrinogen
C-reactive protein (CRP) and fibrinogen are two inflammatory markers that have been shown to be associated with PAD in a number
of studies. In an analysis from the Physician's Health Study, each
was found to be significantly associated with PAD in multivariable
36
Both the
A study of
The 5 μmol/L
9
The MESA
51
A
models, with odds ratios for the upper versus lower population
quartiles of 2.2 for fibrinogen and 2.8 for CRP.60 However, adding
both variables to risk prediction models did not improve the accuracy of prediction because they are significantly intercorrelated. Of
the index studies, CRP was studied only in the MESA, and it was
not significant in multivariable analysis.
included in four of the five studies and was significantly associated
with PAD in multivariable analysis in three of them.
ies have also reported significant and independent associations of
PAD with CRP
75
and fibrinogen.
36,78
51
However, fibrinogen was
9,30,51
Other Risk Factors
A variety of other potential risk factors for PAD have been examined. In several studies, various measures of oral health have been
shown to be independently associated with PAD, possibly based
on common inflammatory pathways.
79
A study in young women
found that self-reported history of various types of infectious diseases, such as chicken pox, shingles, mumps, pneumonia, chronic
bronchitis, or peptic ulcer, was independently and significantly
related to PAD.
associated with PAD as diagnosed by ABI.
Psychosocial factors were found to be associated with PAD in
one large cohort in Scotland,
75
Another study found that a history of arthritis was
80
whereas in a large study of Israeli
6
men, anxiety, job-related stress, and manner of coping with jobrelated conflicts were all significantly related to incident claudication even after adjustment for traditional risk factors.
patients with PAD, depressive symptoms were found to be associated with poorer lower-extremity functioning.
81
Genetic factors appear to have a role in PAD, but data are limited.
In a study of fraternal and identical twins, Carmelli et al. estimated
that 48% of the variability in ABI could be explained by additive
genetic effects.
82
It has also been shown that familial hypercholester-
olemia, a genetic disorder, is related to a higher prevalence of PAD.
Other possible risk factors for which some supporting data exist
include antiphospholipid antibodies,
sedentary lifestyle.
87
Possible protective effects have been reported
for hormone replacement therapy,
Initiative randomized clinical trial of combined estrogen/progestin
therapy showed no effect on the incidence of PAD.
84,85
hypothyroidism,86 and
88
but the Women's Health
89
Interaction and Risk Factor Comparisons
Some research has been conducted into potential variations in
the significance and strength of various risk factors as they are
estimated in different subgroups and for different PAD-related
outcomes.
Differences in the relative strength and significance of risk factors in men and women have been examined in several studies.
Many of these studies have concluded that risk factors do not differ
substantially in men and women. In the Rotterdam Study, separate
models for men and women were compared and failed to reveal
differences in risk factors for PAD.
Framingham Offspring cohorts, testing for statistical interactions
between sex and risk factors failed to provide any evidence of such
interactions.
States (age 65 and older) found similar risk factor associations with
78
30,50
One study of Medicare beneficiaries in the United
ABI in men and in women, the exceptions being total and LDL cholesterol levels, which were related to ABI in women but not in men.
Meijer et al. looked at whether severe PAD, diagnosed based on
ABI of less than 0.7, had different risk factors than ABI diagnosed
based on the traditional cut-point of 0.9.
direction and magnitude of odds ratios were similar for most risk
factors under the two criteria. Point estimates suggested that age
and current smoking were greater risk factors for conventionally
defined PAD, whereas diabetes was more important for severe PAD;
however, the 95% CIs overlapped in all cases.
Many risk factors that have been studied for their relationship to
PAD were originally identified as risk factors for ischemic heart disease. In the most formal comparison of the relative significance and
9
In the large Framingham and
9
In their analysis, the
Other stud-
1
Among
83
15

strength of risk factors for PAD versus ischemic heart disease, the
same risk factors were analyzed for their association with the two
diseases in the Edinburgh Artery Study cohort.
49
In that study, only
the association with smoking was significantly different for PAD
versus ischemic heart disease, with a higher association with PAD.
Especially strong or consistent relationships to PAD that were suggested for triglycerides and homocysteine were generally not borne
out in later studies, as described earlier. In general among risk factors, only smoking and possibly more severe diabetes seem to show
stronger associations with PAD than with ischemic heart disease.
Progression of Peripheral Artery Disease
Little is known about the early natural history of PAD, particularly
the progression from asymptomatic to early symptomatic disease.
Average annual change in ABI has been estimated as 0.01 and 0.02
in various groups,
90,91
but these figures may be somewhat misleading because an average change in ABI masks a variety of changes
of different directions and magnitudes.
A more meaningful approach may be to look at the percentage of the population achieving some categorically defined measure of change. The CHS, a population-based study, found that over
6 years of follow-up, 9.5% of persons showed incident PAD, defined
as an ABI drop of more than 0.15 to a level of 0.9 or lower.92 Nicoloff
et al. found that in 5 years, 37% of patients experienced a significant (≥0.15) worsening of ABI, whereas 22% of patients experienced clinical progression of PAD based on a change in symptoms
or a need for surgical intervention.
93
Among 415 English smokers
with PAD referred for a surgical opinion, about half experienced a
significant (≥
0.14) drop in ABI over the following 48 months.63 In
a group of German PAD patients, PAD was reported to progress in
18.6% of patients during an average follow-up of 64 months, based
on a variety of criteria including change in ABI.94 Bird et al. defined
a ranked series of six categories of PAD defined based on ABI and
other tests; in a study of patients referred to a vascular laboratory,
30.2% of limbs progressed to a more serious category of PAD over
an average follow-up time of 4.6 years, but 22.8% of limbs regressed
to a less severe category during the same period.
In a study based on angiography, 9.1% of patients annually were
found to have evidence of progression of PAD.
development of rest pain or gangrene as the criteria for PAD progression, PAD progressed in 2.5% of patients annually.
90
95
In a study using
87
In the latter
study, it was noted that PAD progressed at a rate approximately three
times greater in the first year following diagnosis than in subsequent
96
years.
Because many studies of PAD progression have used subjects
whose recruitment is linked to the referral for diagnostic testing, estimates of progression from such studies may be appropriate only for
newly diagnosed populations, particularly if follow-up time is short.
Data on risk factors associated with progression of PAD are relatively
sparse. In the CHS, significant independent predictors of decline were
age, cigarette smoking, diabetes, and dyslipidemia.
92
One report showed
age, diabetes, classic claudication, previous intervention, and PAD in the
contralateral leg to be independently predictive of PAD progression.
90
One study of English smokers with PAD identified hypertriglyceridemia as the most important independent risk factor for progression of
PAD and onset of critical ischemia.
been shown to be associated with an increased risk of need for vascular intervention.
97
Patients with premature PAD (onset of symptoms
at or before age 45) appear to have more rapid progression of disease
and generally poorer outcomes.
63
Hemorheological factors have
98–102
Recent data suggest that while
PAD prog ressi on in large arteries was related to smoking, the TC/HDL-C
ratio, lipoprotein(a) (lp[a]), and high-sensitivity CRP assay (hs-CRP),
only diabetes was associated with progression in smaller arteries.
103
Co-Prevalence of Peripheral Artery
Disease and Other Atherosclerotic Disease
Given the common risk factors for PAD and other cardiovascular
and cerebrovascular diseases, it is not surprising that cross-sectionally, people with PAD are more likely to have these other disorders,
and vice versa. Among 5084 Medicare beneficiaries in the CHS,
prevalence of history of MI was 2.5 times as high in subjects with
PAD (based on ABI < 0.9) than those without. For angina, congestive
heart failure (CHF), stroke, and transient ischemic attack (TIA), the
prevalences were 1.9, 3.3, 3.1, and 2.3 times as high, respectively.
15
Conversely, prevalence of PAD was 2.1 times as high in patients
with a history of MI than in those without. Corresponding ratios
for angina, CHF, stroke, and TIA were 1.7, 2.6, 2.4, and 2.1, respec-
15
tively.
Other studies have found similar cross-sectional correla-
44,104,105
tions.
elevated prevalence of carotid artery stenosis,
but significant correlation between severities of the two diseases
has been demonstrated.
Subjects with PAD have also been shown to have an
108
106,107
and a modest
Peripheral Artery Disease as a Predictor
of Mortality and Morbidity
Going beyond the cross-sectional associations discussed earlier,
it has been shown that PAD is prospectively related to morbidity
or mortality from other types of atherosclerotic disease, even after
adjustment for known common risk factors. Although PAD seems
unlikely to directly cause these other diseases, presence of PAD
may serve as a marker for underlying atherosclerotic processes or
susceptibilities affecting other vascular beds. These prospective
relationships are clinically important to the extent that PAD has
prognostic value independent of other known risk factors.
Attempts to elucidate this association epidemiologically began
with studies of patients having symptomatic PAD in the form of
intermittent claudication. Elevated mortality rates among subjects
with claudication were reported in the 1970s and 1980s in the
Framingham cohort, although this excess risk was markedly attenuated when subjects with baseline cerebrovascular and CHD were
excluded.
association between claudication and total or cardiovascular mortality in men after adjustment for cardiovascular risk factors and
baseline cardiovascular disease.
increased mortality risk among claudicants but did not fully adjust
for the conventional cardiovascular risk factors.
a large and methodologically rigorous study, data from the 18,403
men in the Whitehall cohort were used to show that after adjusting for cardiovascular risk factors, claudication was a significant
predictor of cardiovascular disease mortality even after excluding
subjects with baseline disease.
permitted further investigation into the association between PAD
and cardiovascular disease. In 1985, it was first demonstrated that
a combination of noninvasive measures, including ABI, were prospectively related to all-cause mortality even after adjustment for
cardiovascular risk factors and exclusion of subjects with baseline
cardiovascular disease.
range of 4 to 5; a later reanalysis of the same cohort with additional mortality follow-up demonstrated elevated relative risks for
cardiovascular disease and CHD in particular, with no significant
increase in noncardiovascular death.
that ABI was related to cardiovascular disease, based on either mortality or combined mortality and mo rbi dit y. This was found to be
true in a variety of populations: vascular laboratory patients,
elderly patients with hypertension,
ment-based cohort from Belgium,
cohort from Scotland,
ies controlled for various known cardiovascular disease risk factors and presence of cardiovascular disease at baseline. Relative
risks reported ranged from roughly 2 to 5. Many of these studies
also found PAD to be significantly associated with incident CHD
in particular, although the very large CHS failed to find such
associations for either total MI or angina.
disease are less conclusive. A 1991 study showed a strong association
between multiple noninvasive measures of PAD and cerebrovascular
37,109,110
Similarly, a 1982 Finnish study failed to find an
111
Other studies demonstrated
38,95,112
However, in
113
Development of the ABI and other noninvasive measures of PAD
114
Relative risks in this study were in the
3
In the 1990s, a number of other prospective studies confirmed
28,115
116
elderly women,
118
16
and the CHS cohort.29 Most of these stud-
the Edinburgh Artery Study
29
117
an employ-
Data regarding the association of PAD with cerebrovascular
219
CH
16
THE EPIDEMIOLOGY OF PERIPHERAL ARTERY DISEASE

220
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
disease morbidity and mortality, with risk ratios of 3.3 for men and
9.0 for women after multivariable adjustment.
119
Data from the
Edinburgh Artery Study also showed such an association based
on ABI, although after multivariable adjustment, the association
persisted for nonfatal but not fatal stroke.
CHS failed to show a relationship between low ABI and incident
CH
16
29
stroke.
Another large study, the ARIC Study, showed a significant
association between ABI as a continuous variable and ischemic
stroke after multivariable adjustment, but failed to show such association when ABI was categorized based on a 0.8 cut-point.
Population studies suggest a high ABI (>1.4), is also associated
with elevated risk of cardiovascular disease.
caused by stiff, often calcified, ankle arteries that may mask underlying PAD.
14
Recently, the MESA reported that both “low” (<1.00)
16
However, data from the
120
32
Such high ABIs are
TABLE 16-5 Peripheral Artery Disease as a Predictor of Coronary Heart and Cerebrovascular Disease Morbidity and Mortality
95% CI
STUDY
Total Mortality
Criqui, 1992 Large-vessel PAD 3.10 1.80 5.30 Adjusted for conventional risk factors; excludes subjects with
Newman, 1993 ABI < 0.9 3.40 1.60 7.10 Adjusted for conventional risk factors; excludes subjects with
Vogt, 1993 ABI < 0.9 3.10 1.50 6.70 Adjusted for conventional risk factors; excludes subjects with
Kornitzer, 1995 ABI < 0.9 2.07 0.90 4.77 Adjusted for conventional risk factors other than blood
Jager, 1999 ABI < 0.9 1.50 0.79 2.84 Adjusted for conventional risk factors
Newman, 1999 ABI < 0.9 1.62 1.24 2.12 Adjusted for conventional risk factors; excludes subjects with
Hooi, 2002 ABI < 0.7 (vs. > 0.95) 2.10 1.60 2.80 Adjusted for conventional risk factors
Cardiovascular Disease Mortality
Criqui, 1992 Large-vessel PAD 6.30 2.60 15.00 Adjusted for conventional risk factors; excludes subjects with
Vogt, 1993 ABI < 0.9 4.50 1.50 6.70 Adjusted for conventional risk factors; excludes subjects with
Kornitzer, 1995 ABI < 0.9 3.29 1.02 10.57 Adjusted for conventional risk factors other than blood
Jager, 1999 ABI < 0.9 2.36 0.92 6.09 Adjusted for conventional risk factors
Newman, 1999 ABI < 0.9 2.03 1.22 3.37 Adjusted for conventional risk factors; excludes subjects with
Hooi, 2002 ABI < 0.7 (vs. > 0.95) 2.30 1.70 3.10 Adjusted for conventional risk factors
Coronary Heart Disease Mortality
Criqui, 1992 Large-vessel PAD 4.30 1.40 12.80 Adjusted for conventional risk factors; excludes subjects with
Kornitzer, 1995 ABI < 0.9 3.63 1.11 11.84
Cardiovascular Morbidity
Newman, 1993 ABI < 0.9 2.10 1.10 4.10 Adjusted for conventional risk factors
Hooi, 2002 ABI < 0.7 (vs. > 0.95) 1.70 1.30 2.40 Adjusted for conventional risk factors
Myocardial Infarction
Newman, 1999 ABI < 0.9 1.40 0.90 2.17 Adjusted for conventional risk factors; excludes subjects with
Stroke
Newman, 1999 ABI < 0.9 1.12 0.74 1.70 Adjusted for conventional risk factors; excludes subjects with
All Coronary Heart Disease Morbidity and Mortality
Criqui, 2010 ABI <1.0 1.87 1.30 2.68 Adjusted for conventional risk factors; excludes subjects with
All Stroke Morbidity and Mortality
Criqui, 2010 ABI < 1.0 1.56 0.92 2.96 Adjusted for conventional risk factors; excludes subjects with
ABI, ankle-brachial index; CHD, coronary heart disease; MI, myocardial infarction; PAD, peripheral artery disease.
PERIPHERAL ARTERY
DISEASE MEASUREMENT
ABI >1.4 2.15 1.09 4.24
ABI > 1.4 2.69 0.97 7.55
HAZARD
RATIO LOWER UPPER
and “high” (>1.40) ABI were associated with increased risk of incident cardiovascular disease events, even after adjustment for traditional and novel risk factors.
121
Interestingly, high ABI showed a
stronger association for stroke than low ABI. Also, this was the first
report to show that the ABI predicted events independent of other
measures of extant atherosclerosis—specifically, coronary artery
calcium, carotid intima media thickness, and major electrocardiographic abnormalities. Recent evidence also indicates that independent of baseline ABI, a more rapid deterioration in ABI carries
a worse prognosis.
122
Table 16-5 provides a summary of studies of the association of
PAD with various mortality and morbidity outcomes. The table is
limited to studies using a noninvasive measure of PAD (usually
ABI at various cut-points), and logistic or proportional hazards
MODEL SPECIFICATIONS
baseline angina, MI, stroke (multiple criteria)
baseline cardiovascular disease
baseline cardiovascular disease
pressure; excludes baseline CHD
baseline cardiovascular disease
baseline angina, MI, stroke (multiple criteria)
baseline cardiovascular disease
pressure; excludes baseline CHD
baseline cardiovascular disease
baseline angina, MI, stroke (multiple criteria)
Adjusted for conventional risk factors other than blood
pressure; excludes baseline CHD
baseline cardiovascular disease
baseline cardiovascular disease
baseline cardiovascular disease
baseline cardiovascular disease

regression models with multivariable adjustment for conventional
cardiovascular risk factors. Results are shown with multivariable
adjustment and after exclusion of subjects with baseline cardiovascular disease, where such exclusion was attempted.
Summary and Conclusions
Peripheral artery disease is atherosclerotic obstruction of the
arteries of the lower extremities. The most common symptom of
PAD is intermittent claudication, which is pain in the legs associated with walking that is relieved by rest. However, noninvasive
measures such as the ABI show that asymptomatic PAD is several times more common in the population than intermittent
claudication. Peripheral artery disease prevalence is sharply age
related, rising to more than 10% among patients in their 60s and
70s. Prevalence appears to be higher among men than women for
moderate to severe disease. Major risk factors for PAD are similar to those for cardiovascular and cerebrovascular disease, with
some differences in the relative importance of factors. Smoking is
a particularly strong risk factor for PAD, as is diabetes. Peripheral
artery disease is cross-sectionally associated with cardiovascular
and cerebrovascular disease. After adjustment for known cardiovascular disease risk factors, PAD is associated with an increased
risk of cardiovascular and cerebrovascular disease, morbidity,
and mortality.
With general aging of the population, it seems likely that PAD will
be increasingly common in the future. Diagnosis and treatment of
PAD in its asymptomatic stage may prove highly beneficial, particularly with respect to interventions aimed at ameliorating risk factors
common to atherosclerotic disease of the several vascular beds.
REFERENCES
1. Bowlin SJ, Medalie JH, Flocke SA, et al: Epidemiology of intermittent claudication in
middle-aged men, Am J Epidemiol 140:418, 1994.
2. Allison MA, Ho E, Denenberg JO, et al: Ethnic-specific prevalence of peripheral arterial
disease in the United States, Am J Prev Med 32:328, 2007.
3. Criqui MH, Langer RD, Fronek A, et al: Mortality over a period of 10 years in patients with
peripheral arterial disease, N Engl J Med 326:381, 1992.
4. Rose GA: The diagnosis of ischaemic heart pain and intermittent claudication in field
surveys, Bull World Health Organ 27:645, 1962.
5. Criqui MH, Denenberg JO, Bird CE, et al: The correlation between symptoms and non-invasive
test results in patients referred for peripheral arterial disease testing, Vasc Med 1:65, 1996.
6. Vogt MT, Cauley JA, Kuller LH, et al: Prevalence and correlates of lower-extremity arterial
disease in elderly women, Am J Epidemiol 137:559, 1993.
7. Winsor T: Influence of arterial disease on the systolic blood pressure gradients of the
extremity, Am J Med Sci 220:117, 1950.
8. Hooi JD, Stoffers HE, Kester AD, et al: Peripheral arterial occlusive disease: prognostic value
of signs, symptoms, and the ankle-brachial pressure index, Med Decis Making 22:99, 2002.
9. Meijer W T, Grobbee DE, Hunink MG, et al: Determinants of peripheral arterial disease in
the elderly: the Rotterdam study, Arch Intern Med 160:2934, 2000.
10. Meijer W T, Hoes AW, Rutgers D, et al: Peripheral arterial disease in the elderly: the
Rotterdam Study, Arterioscler Thromb Vasc Biol 18:185, 1998.
11. Yao ST, Hobbs JT, Irvine WT: Ankle systolic pressure measurements in arterial disease
affecting the lower extremities, Br J Surg 56:676, 1969.
12. Ouriel K, McDonnell AE, Metz CE, et al: Critical evaluation of stress testing in the diagnosis
of peripheral vascular disease, Surgery 91:686, 1982.
13. Lijmer JG, Hunink MG, van den Dungen JJ, et al: ROC analysis of noninvasive tests for
peripheral arterial disease, J Ultrasound Med Biol 22:391, 1996.
14. Aboyans V, Ho E, Denenberg JO, et al: The association between elevated ankle systolic
pressures and peripheral occlusive arterial disease in diabetic and non-diabetic subjects,
J Vasc Surg 48:1197, 2008.
15. Newman AB, Siscovick DS, Manolio TA, et al: Ank le-arm index as a marker of atherosclerosis
in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative
Research Group, Circulation 88:837, 1993.
16. Leng GC, Fowkes FG, Lee AJ, et al: Use of ankle-brachial pressure index to predict
cardiovascular events and death: a cohort study, BMJ 313:1440, 1996.
17. McDermott MM, Fried L, Simonsick E, et al: Asymptomatic peripheral arterial disease
is independently associated with impaired lower extremity functioning: the Women's
Health and Aging Study, Circulation 101:1007, 2000.
18. McDermott MM, Liu K, O'Brien E, et al: Measuring physical activity in peripheral arterial
disease: a comparison of two physical activity questionnaires with an accelerometer,
Angiology 51:91, 2000.
19. McDermott MM, Ferrucci L, Simonsick EM, et al: The ankle-brachial index and change in
lower-extremity functioning over time: the Women's Health and Aging Study, J A m Geriatr
Soc 50:238, 2002.
20. McDermott MM, Criqui MH, Liu K, et al: Lower ankle-brachial index, as calculated by
averaging the dorsalis pedis and posterior tibial arterial pressures, and association with
leg functioning in peripheral arterial disease, J Vasc Surg 32:116, 2000.
21. Aboyans V, Lacroix P, Lebourdon A, et al: The intra- and interobserver variability of ankle-arm
blood pressure index according to its mode of calculation, J Clin Epidemiol 56:215, 2003.
22. Shadman R, Criqui MH, Bundens WP, et al: Subclavian artery stenosis: prevalence, risk
factors, and association with cardiovascular diseases, J Am Coll Cardiol 44:618, 2004.
23. Fowkes FG, Housley E, Cawood EH, et al: Edinburgh Artery Study: Prevalence of
asymptomatic and symptomatic peripheral arterial disease in the general population, Int
J Epidemiol 20:384, 1991.
24. Hiatt WR, Hoag S, Hamman RF: Effect of diagnostic criteria on the prevalence of peripheral
arterial disease: the San Luis Valley Diabetes Study, Circulation 91:1472, 1995.
25. Aboyans V, Criqui MH, McClelland RL, et al: Intrinsic contribution of gender and ethnicity
to normal ankle-brachial index values: the Multi-Ethnic Study of Atherosclerosis (MESA), J
Vasc Surg 45:319, 2007.
26. Kreines K, Johnson E, Albrink M, et al: The course of peripheral vascular disease in noninsulin-dependent diabetes, Diabetes Care 8:235, 1985.
27. Orchard TJ, Strandness DE Jr.: Assessment of peripheral vascular disease in diabetes.
Report and recommendations of an international workshop sponsored by the American
Heart Association and the American Diabetes Association, 18-20 September 1992, New
Orleans, Louisiana, Diabetes Care 16:1199, 1993.
28. McKenna M, Wolfson S, Kuller L: The ratio of ankle and arm arterial pressure as an
independent predictor of mortality, Atherosclerosis 87:119, 1991.
29. Newman AB, Shemanski L, Manolio TA, et al: Ankle-arm index as a predictor of
cardiovascular disease and mortality in the Cardiovascular Health Study. The
Cardiovascular Health Study Group, Arterioscler Thromb Vasc Biol 19:538, 1999.
30. Murabito JM, Evans JC, Nieto K, et al: Prevalence and clinical correlates of peripheral
arterial disease in the Framingham Offspring Study, Am Heart J 143:961, 2002.
31. Wang JC, Criqui MH, Denenberg JO, et al: Exertional leg pain in patients with and without
peripheral arterial disease, Circulation 112:3501, 2005.
32. Ankle Brachial Index Collaboration: Ankle brachial index combined with Framingham risk
score to predict cardiovascular events and mortality. A meta-analysis, JAMA 300:197, 2008.
33. Criqui MH, Fronek A, Barrett-Connor E, et al: The prevalence of peripheral arterial disease
in a defined population, Circulation 71:510, 1985.
34. Beks PJ, Mackaay AJ, de Neeling JN, et al: Peripheral arterial disease in relation to glycaemic
level in an elderly Caucasian population: the Hoorn study, Diabetologia 38:86, 1995.
35. Stoffers HE, Rinkens PE, Kester AD, et al: The prevalence of asymptomatic and
unrecognized peripheral arterial occlusive disease, Int J Epidemiol 25:282, 1996.
36. Curb JD, Masaki K, Rodriguez BL, et al: Peripheral artery disease and cardiovascular risk factors
in the elderly. The Honolulu Heart Program, Arterioscler Thromb Vasc Biol 16:1495, 1996.
37. Kannel WB, McGee DL: Update on some epidemiologic features of intermittent
claudication: the Framingham Study, J Am Geriatr Soc 33:13, 1985.
38. Dagenais GR, Maurice S, Robitaille NM, et al: Intermittent claudication in Quebec men
from 1974-1986: the Quebec Cardiovascular Study, Clin Invest Med 14:93, 1991.
39. Bainton D, Sweetnam P, Baker I, et al: Peripheral vascular disease: consequence for
survival and association with risk factors in the Speedwell prospective heart disease
study, Br Heart J 72:128, 1994.
40. Leng GC, Lee AJ, Fowkes FG, et al: Incidence, natural history and cardiovascular events in
symptomatic and asymptomatic peripheral arterial disease in the general population, Int
J Epidemiol 25:1172, 1996.
41. Ingolfsson IO, Sigurdsson G, Sigvaldason H, et al: A marked decline in the prevalence
and incidence of intermittent claudication in Icelandic men 1968-1986: a strong
relationship to smoking and serum cholesterol—the Reykjavik Study, J Clin Epidemiol
47:1237, 1994.
42. Hooi JD, Kester AD, Stoffers HE, et al: Incidence of and risk factors for asymptomatic
peripheral arterial occlusive disease: a longitudinal study, Am J Epidemiol 153:666, 2001.
43. Gallotta G, Iazzetta N, Milan G, et al: Prevalence of peripheral arterial disease in an elderly
rural population of southern Italy, Gerontology 43:289, 1997.
44. Zheng ZJ, Sharrett AR, Chambless LE, et al: Associations of ankle-brachial index with
clinical coronary heart disease, stroke and preclinical carotid and popliteal atherosclerosis:
the Atherosclerosis Risk in Communities (ARIC) Study, Atherosclerosis 131:115, 1997.
45. McDermott MM, Liu K, Criqui MH, et al: The ankle brachial index and subclinical cardiac and
carotid disease: the Multi-Ethnic Study of Atherosclerosis, Am J Epidemiol 162:33, 2005.
46. Faulkner KW, House AK, Castleden WM: The effect of cessation of smoking on the
accumulative survival rates of patients with symptomatic peripheral vascular disease,
Med J Aust 1:217, 1983.
47. Quick CR, Cotton LT: The measured effect of stopping smoking on intermittent
claudication, Br J Surg 69(Suppl):S24, 1982.
48. Jonason T, Bergstrom R: Cessation of smoking in patients with intermittent claudication:
effects on the risk of peripheral vascular complications, myocardial infarction and
mortality, Acta Med Scand 221:253, 1987.
49. Fowkes FG, Housley E, Riemersma RA, et al: Smoking, lipids, glucose intolerance, and
blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart
disease in the Edinburgh Artery Study, Am J Epidemiol 135:331, 1992.
50. Murabito JM, D'Agostino RB, Silbershatz H, et al: Intermittent claudication: a risk profile
from The Framingham Heart Study, Circulation 96:44, 1997.
51. Allison MA, Criqui MH, McClelland RL, et al: the effect of novel cardiovascular risk factors
on the ethnic-specific odds for peripheral arterial disease in the Multi-Ethnic Study of
Atherosclerosis (MESA), J Am Coll Cardiol 48:1190, 2006.
52. Criqui MH, Vargas V, Denenberg JO, et al: Ethnicity and peripheral arterial disease: the San
Diego Population Study, Circulation 112:2703, 2005.
53. Katsilambros NL, Tsapogas PC, Arvanitis MP, et al: Risk factors for lower extremity arterial
disease in non-insulin-dependent diabetic persons, Diabet Med 13:243, 1996.
54. Tseng CH: Prevalence and risk factors of peripheral arterial obstructive disease in
Taiwanese type 2 diabetic patients, Angiology 54:331, 2003.
55. Kallio M, Forsblom C, Groop PH, et al: Development of new peripheral arterial occlusive
disease in patients with type 2 diabetes during a mean follow-up of 11 years, Diabetes
Care 26:1241, 2003.
56. Jude EB, Oyibo SO, Chalmers N, et al: Peripheral arterial disease in diabetic and nondiabetic
patients: a comparison of severity and outcome, Diabetes Care 24:1433, 2001.
221
CH
16
THE EPIDEMIOLOGY OF PERIPHERAL ARTERY DISEASE

222
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
57. Haltmayer M, Mueller T, Horvath W, et al: Impact of atherosclerotic risk factors on the
anatomical distribution of peripheral arterial disease, Int Angiol 20:200, 2001.
58. Natarajan S, Glick H, Criqui M, et al: Cholesterol measures to identify and treat individuals
at risk for coronary disease, Am J Prev Med 25:50, 2003.
59. Ness J, Aronow WS, Ahn C: Risk factors for symptomatic peripheral arterial disease in older
persons in an academic hospital-based geriatrics practice, J Am Geriatr Soc 48:312, 2000.
60. Ridker PM, Stampfer MJ, Rifai N: Novel risk factors for systemic atherosclerosis: a
CH
16
comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard
cholesterol screening as predictors of peripheral arterial disease, JAMA 285:2481, 2001.
61. Fowkes FG: Epidemiology of atherosclerotic arterial disease in the lower limbs, Eur J Vasc
Surg 2:2831, 1988.
62. Cheng SW, Ting AC, Wong J: Fasting total plasma homocysteine and atherosclerotic
peripheral vascular disease, Ann Vasc Surg 11:217, 1997.
63. Smith I, Franks PJ, Greenhalgh RM, et al: The influence of smoking cessation and
hypertriglyceridaemia on the progression of peripheral arterial disease and the onset of
critical ischaemia, Eur J Vasc Endovasc Surg 11:402, 1996.
64. Mowat BF, Skinner ER, Wilson HM, et al: Alterations in plasma lipids, lipoproteins and high
density lipoprotein subfractions in peripheral arterial disease, Atherosclerosis 131:161,
1997.
65. Criqui MH, Denenberg JO, Langer RD, et al: Peripheral arterial disease and hypertension. In
Izzo JL, Black HR, editors: Hypertension primer, Dallas, 2003, American Heart Association, 250.
66. Dormandy J, Heeck L, Vig S: Predictors of early disease in the lower limbs, Semin Vasc Surg
12:109, 1999.
67. Tseng CH: Prevalence and risk factors of peripheral arterial obstructive disease in
Taiwanese type 2 diabetic patients, Angiology 54:331, 2003.
68. Vliegenthart R, Geleijnse JM, Hofman A, et al: Alcohol consumption and risk of peripheral
arterial disease: the Rotterdam Study, Am J Epidemiol 155:332, 2002.
69. Jepson RG, Fowkes FG, Donnan PT, et al: Alcohol intake as a risk factor for peripheral
arterial disease in the general population in the Edinburgh Artery Study, Eur J Epidemiol
11:9, 1995.
70. Fabsitz RR, Sidawy AN, Go O, et al: Prevalence of peripheral arterial disease and associated
risk factors in American Indians: the Strong Heart Study, Am J Epidemiol 149:330, 1999.
71. Camargo CA Jr., Stampfer MJ, Glynn RJ, et al: Prospective study of moderate alcohol
consumption and risk of peripheral arterial disease in U.S. male physicians, Circulation
95:577, 1997.
72. Hobbs SD, Wilmink AB, Bradbury AW: Ethnicity and peripheral arterial disease, Eur J Vasc
Endovasc Surg 25:505, 2003.
73. Ix JH, Allison MA, Denenberg JO, et al: Novel cardiovascular risk factors do not completely
explain the higher prevalence of peripheral arterial disease among African Americans.
The San Diego Population Study, J Am Coll Cardiol 51:2347, 2008.
74. Boushey CJ, Beresford SA, Omenn GS, et al: A quantitative assessment of plasma
homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic
acid intakes, JAMA 274:1049, 1995.
75. Bloemenkamp DG, van den Bosch MA, Mali WP, et al: Novel risk factors for peripheral
arterial disease in young women, Am J Med 113:462, 2002.
76. Graham IM, Daly LE, Refsum HM, et al: Plasma homocysteine as a risk factor for vascular
disease. The European Concerted Action Project, JAMA 277:1775, 1997.
77. Hoogeveen EK, Kostense PJ, Beks PJ, et al: Hyperhomocysteinemia is associated with an
increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes
mellitus: a population-based study, Arterioscler Thromb Vasc Biol 18:133, 1998.
78. Taylor LM Jr., Moneta GL, Sexton GJ, et al: Prospective blinded study of the relationship
between plasma homocysteine and progression of symptomatic peripheral arterial
disease, J Vasc Surg 29:8, 1999.
79. Hung HC, Willett W, Merchant A, et al: Oral health and peripheral arterial disease,
Circulation 107:1152, 2003.
80. Whiteman MC, Deary IJ, Fowkes FG: Personality and social predictors of atherosclerotic
progression: Edinburgh Artery Study, Psychosom Med 62:703, 2000.
81. McDermott MM, Greenland P, Guralnik JM, et al: Depressive symptoms and lower extremity
functioning in men and women with peripheral arterial disease, J Gen Intern Med 18:461, 2003.
82. Carmelli D, Fabsitz RR, Swan GE, et al: Contribution of genetic and environmental
influences to ankle-brachial blood pressure index in the NHLBI Twin Study. National
Heart, Lung, and Blood Institute, Am J Epidemiol 151:452, 2000.
83. Kroon AA, Ajubi N, van Asten WN, et al: The prevalence of peripheral vascular disease in
familial hypercholesterolaemia, J Intern Med 238:451, 1995.
84. Taylor LM Jr., Chitwood RW, Dalman RL, et al: Antiphospholipid antibodies in vascular
surgery patients: a cross-sectional study, Ann Surg 220:544, 1994.
85. Lam EY, Taylor LM Jr., Landry GJ, et al: Relationship between antiphospholipid antibodies
and progression of lower extremity arterial occlusive disease after lower extremity bypass
operations, J Vasc Surg 33:976, 2001.
86. Mya MM, Aronow WS: Increased prevalence of peripheral arterial disease in older men
and women with subclinical hypothyroidism, J Gerontol A Biol Sci Med Sci 58:68, 2003.
87. Asgeirsdottir LP, Agnarsson U, Jonsson GS: Lower extremity blood flow in healthy men:
effect of smoking, cholesterol, and physical activity—a Doppler study, Angiology 52:437,
2001.
88. Westendorp IC, in't Veld BA, Grobbee DE, et al: Hormone replacement therapy and
peripheral arterial disease: the Rotterdam Study, Arch Intern Med 160:2498, 2000.
89. Hsia J, Criqui MH, Rodabough R, et al: Estrogen plus progestin and the risk of peripheral
arterial disease: the Women's Health Initiative, Circulation 109:620, 2004.
90. Bird CE, Criqui MH, Fronek A, et al: Quantitative and qualitative progression of peripheral
arterial disease by non-invasive testing, Vasc Med 4:15, 1999.
91. Fowkes FG, Lowe GD, Housley E, et al: Cross-linked fibrin degradation products, progression
of peripheral arterial disease, and risk of coronary heart disease, Lancet 342:84, 1993.
92. Kennedy M, Solomon C, Manolio TA, et al: Risk factors for declining ankle-brachial index
in men and women 65 years or older: the Cardiovascular Health Study, Arch Intern Med
165:1896, 2005.
93. Nicoloff AD, Taylor LM Jr., Sexton GJ, et al: Relationship between site of initial symptoms
and subsequent progression of disease in a prospective study of atherosclerosis
progression in patients receiving long-term treatment for symptomatic peripheral arterial
disease, J Vasc Surg 35:38, 2002.
94. Taute BM, Gläser C, Taute R, et al: Progression of atherosclerosis in patients with peripheral
arterial disease as a function of angiotensin-converting enzyme gene insertion/deletion
polymorphism, Angiology 53:375, 2002.
95. Walsh DB, Gilbertson JJ, Zwolak RM, et al: The natural history of superficial femoral artery
stenoses, J Vasc Surg 14:299, 1991.
96. Jelnes R, Gaardsting O, Hougaard Jensen K, et al: Fate in intermittent claudication:
outcome and risk factors, Br Med J (Clin Res Ed) 293:1137, 1986.
97. Smith FB, Lowe GD, Lee AJ, et al: Smoking, hemorheologic factors, and progression of
peripheral arterial disease in patients with claudication, J Vasc Surg 28:129, 1998.
98. McCready RA, Vincent AE, Schwartz RW, et al: Atherosclerosis in the young: a virulent
disease, Surgery 96:863, 1984.
99. Pairolero PC, Joyce JW, Skinner CR, et al: Lower limb ischemia in young adults: prognostic
implications, J Vasc Surg 1:459, 1984.
100. Hallett JW Jr., Greenwood LH, Robison JG: Lower extremity arterial disease in young
adults: a systematic approach to early diagnosis, Ann Surg 202:647, 1985.
101. Valentine RJ, MacGillivray DC, DeNobile JW, et al: Intermittent claudication caused by
atherosclerosis in patients aged forty years and younger, Surgery 107:560, 1990.
102. Levy PJ, Hornung CA, Haynes JL, et al: Lower extremity ischemia in adults younger than
forty years of age: a community-wide survey of premature atherosclerotic arterial disease,
J Vasc Surg 19:873, 1994.
103. Aboyans V, Criqui MH, Denenberg JO, et al: Risk factors for progression of peripheral
arterial disease in large and small vessels, Circulation 113:2623, 2006.
104. Criqui MH, Denenberg JO, Langer RD, et al: The epidemiology of peripheral arterial
disease: importance of identifying the population at risk, Vasc Med 2:221, 1997.
105. Ness J, Aronow WS: Prevalence of coexistence of coronary artery disease, ischemic stroke,
and peripheral arterial disease in older persons, mean age 80 years, in an academic
hospital-based geriatrics practice, J Am Geriatr Soc 47:1255, 1999.
106. Alexandrova NA, Gibson WC, Norris JW, et al: Carotid artery stenosis in peripheral vascular
disease, J Vasc Surg 23:645, 1996.
107. Pilcher JM, Danaher J, Khaw KT: The prevalence of asymptomatic carotid artery disease in
patients with peripheral vascular disease, Clin Radiol 55:56, 2000.
108. Long TH, Criqui MH, Vasilevskis EE, et al: The correlation between the severity of peripheral
arterial disease and carotid occlusive disease, Vasc Med 4:135, 1999.
109. Kannel WB, Skinner JJ Jr., Schwartz MJ, et al: Intermittent claudication: incidence in the
Framingham Study, Circulation 41:875, 1970.
110. Kannel WB, Shurtleff D: The natural history of arteriosclerosis obliterans, Cardiovasc Clin
3:37, 1971.
111. Reunanen A, Takkunen H, Aromaa A: Prevalence of intermittent claudication and its effect
on mortality, Acta Med Scand 211:249, 1982.
112. Kallero KS: Mortality and morbidity in patients with intermittent claudication as defined by
venous occlusion plethysmography: a ten-year follow-up study, J Chronic Dis 34:455, 1981.
113. Smith GD, Shipley MJ, Rose G: Intermittent claudication, heart disease risk factors, and
mortality: the Whitehall Study, Circulation 82:1925, 1990.
114. Criqui MH, Coughlin SS, Fronek A: Noninvasively diagnosed peripheral arterial disease as
a predictor of mortality: results from a prospective study, Circulation 72:768, 1985.
115. McDermott MM, Feinglass J, Slavensky R, et al: The ankle-brachial index as a predictor of
survival in patients with peripheral vascular disease, J Gen Intern Med 9:445, 1994.
116. Newman AB, Sutton-Tyrrell K, Vogt MT, et al: Morbidity and mortality in hypertensive
adults with a low ankle/arm blood pressure index, JAMA 270:487, 1993.
117. Vogt MT, Cauley JA, Newman AB, et al: Decreased ankle/arm blood pressure index and
mortality in elderly women, JAMA 270:465, 1993.
118. Kornitzer M, Dramaix M, Sobolski J, et al: Ankle/arm pressure index in asymptomatic
middle-aged males: an independent predictor of ten-year coronary heart disease
mortality, Angiology 46:211, 1995.
119. Criqui MH, Langer RD, Fronek A, et al: Coronary disease and stroke in patients with largevessel peripheral arterial disease, Drugs 42(Suppl 5):16, 1991.
120. Tsai AW, Folsom AR, Rosamond WD, et al: Ankle-brachial index and 7-year ischemic stroke
incidence: the ARIC study, Stroke 32:1721, 2001.
121. Criqui MH, McClelland RL, McDermott MM, et al: The ankle-brachial index and incident
cardiovascular events in the MESA (Multi-Ethnic Study of Atherosclerosis), J Am Coll
Cardiol 56:1506, 2010.
122. Criqui MH, Ninomiya JK, Wingard DL, et al: Progression of peripheral arterial disease
predicts cardiovascular disease morbidity and mortality, J Am Coll Cardiol 52:1736, 2008.
Соседние файлы в папке Библиотека им академика М.И. Перельмана
